At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
bepotastine besilate nasal product - low dose +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
In Brief
A Phase 2 clinical trial evaluating bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, and 2 other interventions for Seasonal Allergic Rhinitis. Completed, enrolled 89 participants across 1 site.
Detailed Summary
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
Primary CompletionAug 2010
First PostedOct 2010
TodayJul 2026
First PostedOct 18, 2010
Enrollment StartMay 1, 2010
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.7 years ago
Interventions
bepotastine besilate nasal product - low dosedrug
sterile nasal product
bepotastine besilate nasal product - medium dosedrug
sterile nasal product
bepotastine besilate nasal product - high dosedrug
sterile nasal product
placebo comparator nasal productdrug
sterile nasal product